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Cancer cells typically demonstrate alteredmorphology during the various stages of disease progression as well asmetastasis.Whilemuch is
known about how altered cell morphology in cancer is a result of genetic regulation, less is known about how changes in cell morphology
affect cell function by influencing gene expression. In this study, we altered cell morphology in different types of cancer cells by disrupting
the actin cytoskeleton or by modulating attachment and observed a rapid up-regulation of growth differentiation factor 15 (GDF15), a
member of the transforming growth factor-beta (TGF-b) super-family. Strikingly, this up-regulation was sustained as long as the cell
morphology remained altered but was reversed upon allowing cell morphology to return to its typical configuration. The potential
significance of these findings was examined in vivo using a mouse model: a small number of cancer cells grown in diffusion chambers that
altered morphology increased mouse serum GDF15. Taken together, we propose that during the process of metastasis, cancer cells
experience changes in cell morphology, resulting in the increased production and secretion of GDF15 into the surrounding environment.
This indicates a possible relationship between serum GDF15 levels and circulating tumor cells may exist. Further investigation into the
exact nature of this relationship is warranted.
J. Cell. Physiol. 229: 362–373, 2014.  2013 Wiley Periodicals, Inc.
Altered cell morphology is a hallmark of cancer but its influence
on the cancer phenotype is not well described. Typically, the
further away cancer cells appear morphologically from their
normal counterparts, the more malignant the cancer becomes.
Despite advances in identifying genetic markers that help
diagnose cancer, cell morphology remains as one of the most
common traits pathologists use routinely to differentiate
between a malignant and normal cell (Gleason and Mellinger,
1974; DeMarzo et al., 2003). Key morphological differences
between a cancer and normal cell include but are not limited to
altered cell shape, a larger nucleus and prominent nucleoli.
Further alterations to cancer cell morphology occur
during metastasis under conditions that either retain or lose
attachment to the extracellular environment. During invasion
through the extracellular matrix, cancer cells undergo
remodeling of the actin cytoskeleton resulting in either an
amoeboid or mesenchymal configuration, while maintaining
attachment with the extracellular environment via adhesion
molecules such as integrins (Friedl and Wolf, 2003; Friedl
and Alexander, 2011). Once these cells intravasate into the
circulation as circulating tumor cells (CTCs), they lose
attachment to the extracellular matrix and as a result, appear
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morphologically different, characterized by a rounded cell body
(Marrinucci et al., 2010; Stott et al., 2010).
While known oncogenes can drive changes to cell
morphology (Russo et al., 1991; Fincham et al., 1999), there is
also evidence that affecting cell morphology can also determine
cell function. For example, cell shape regulation by affecting
attachment to a growth surface had the potential to induce
stem cells to differentiate into different cell types by activating
signal transduction pathways such as RhoA/ROCK (McBeath
et al., 2004; Zare-Mehrjardi et al., 2011). In addition, fibroblasts
grown in a synthetic three-dimensional matrix had different
gene expression profiles when compared to the same
fibroblasts grown on a two-dimensional platform made of the
same material (Hillmann et al., 1999; Webb et al., 2003). It was
also demonstrated that activation of ROCK when cells were
subjected to physical forces such as shear stress can affect
physical parameters of the cells such as stiffness of the
cytoplasm (Lee et al., 2006). This is indicative that alterations to
cell shape brought about by changes in the physical
environment of the cell have the potential to activate signal
transduction pathways that affect cell function at both the gene
expression and the physical level (Liu et al., 2006). The
importance of extracellular environment is also well studied in
diseases such as breast cancer, where malignant breast cancer
cells grown ex vivo in tissue culture can be driven to
differentiate into normal duct forming structures by growing
the cells in a different physical environment containing three-
dimensional extracellular matrix components (Weaver et al.,
1997; Schedin and Keely, 2011). There is also growing evidence
that the physical microenvironment can promote drug
resistance in cancer (Desoize et al., 1998; Ghods et al., 2007).
The physical environment is clearly important not only in
facilitating cancer progression; but also as an obstacle to
effective cancer therapy.
Thus, the physical environment is capable of affecting cell
morphology and function by regulating gene expression.
Identifying which genes in cancer respond to alterations in
morphology may help us better understand cancer biology. In
this study, we employed three different strategies to alter cell
morphology. The first strategy consisted of remodeling the
actin cytoskeleton while allowing attachment to a growth
substrate, while the second strategy involved loss of adhesion.
The third strategy grew cells in a three-dimensional matrix of
different collagen I concentration.We further describe a target
gene, GDF15, whose expression closely follows changes to cell
morphology. This gene is implicated in multiple cancer types
and may reflect a common response mounted by cells in the
face of altered morphology.
Materials and Methods
Cell culture
All cell lines were purchased from American Type Culture
Collection and authentication was done by provider using short
tandem repeat profiling. LNCaP, PC3, and DU145 prostate
carcinoma cell lines were cultured in 1 RPMI-1640 media
(Invitrogen, Grand Island, NY) supplemented with 10% fetal bovine
serum (FBS) (Gemini Bio-Products, West Sacaramento, CA) and
50mg/ml of penicillin/streptomycin (Corning, Cellgro, Manassas,
VA). HCT-116 colon cancer cell line was grown in McCoy’s Media
(Invitrogen) supplemented with 10% FBS and 50mg/ml penicillin/
streptomycin.
Altering morphology with latrunculin B or jasplakinolide
Cells were treated with either 500 nM latrunculin B (Lat B) (Enzo
Life Sciences, Farmingdale, NY) or 100 nM jasplakinolide (Jpk) (Life
Technologies, Grand Island, NY) drug for 8 h. To allow cell
morphology to recover, medium containing drug was removed
after 8 h and fresh media added. Phase images were acquired using
a Zeiss Cell Observer Imaging system (Carl Zeiss, Inc., Germany)
at 20 magnification.
Altering morphology by preventing attachment to tissue
culture dish
Tissue culture dishes were coated with poly(2-hydroxyethyl
methacrylate) (PHEMA) (Sigma-Aldrich, St. Louis, MO) at a
concentration of 0.8mg/cm2. Coated dishes were rinsed twice
with sterile 1 PBS before seeding cells in growth medium. To
assay conditioned media for measuring GDF15 by ELISA, growth
media was changed 24 h before harvesting. Harvested cell
suspensions were centrifuged at 300g for 5min and supernatant
was collected for ELISA.
Altering morphology by growing cells in collagen I
matrix
Human collagen type I (BDBioscience, San Jose, CA)was diluted to
the appropriate concentration using sterile 4mM HCl and 10
RPMI was added to neutralize pH. Freshly trypsinized cells re-
suspended in FBS were added to the neutralized collagen I. The
collagen gel was then allowed to polymerize at 37˚C, 5% CO2, 90%
humidity overnight. To harvest the cells from collagen gels,
collagenase (Sigma-Aldrich) was added and incubated at 37˚C for
15min. Cell pellet was harvested from gel by centrifuge at 300g for
5min.
Signal transduction pathway inhibitors
Twenty micromolars of PKC inhibitor H7 and 2mM of p38MAPK
inhibitor SB203580 (Enzo Life Science, Farmingdale, NY) were
added in combination with Lat B, Jpk, or cells grown on PHEMA-
coated dishes and incubated for 8 h before harvesting cell lysates.
These inhibitors were chosen based on previously observed
findings that activation of protein kinase C (PKC) or p38 mitogen-
activated protein kinase (p38MAPK) through the addition of
phorbol 12-myristate 13-acetate (PMA) or vitamin E respectively
up-regulates GDF15 expression (Shim and Eling, 2005, 2008).
RNA isolation and quantitative reverse transcription
PCR
RNA was isolated from cells using RNeasy spin column mini kit
(Qiagen, Germany) and 1mg of RNA was converted to cDNA
using the iSCRIPT cDNA synthesis kit (BioRad, Hercules, CA).
Quantitative PCR was performed using SYBR green master mix
(BioRad) and ran on a BioRad CFX-96 Real-time system. Primers
were designed using Vector NTI. Sequence of GDF15 forward
primer 50-TCAAGGTCGTGGGACGTGACA-30. Sequence of
GDF15 reverse primer 50-GCCGTGCGGACGAAGATTCT-30.
TATA-binding protein (TBP) was used as internal reference.
Sequence of TBP forward primer 50-GAATATAATCCCAAGC-
GGTTTG-30. Sequence of TBP reverse primers 50-ACTTCA-
CATCACAGCTCCCC-30. DCT was calculated by subtracting
TBP CT values from GDF15 CT values and ratio of GDF15 to TBP
was calculated subsequently using 2DCT.
Immunostaining for cell morphology analysis
Cells were washed with 1 PBS and then fixed with 3.7%
paraformaldehyde for 10min. Fixed cells were rinsed twice with
1 PBS and permeabilized with 1 PBS/0.1% Triton X-100 for
5min. After permeabilization, rhodamine phalloidin was added to
stain cellular actin and nuclear DNA counterstain was done with
DAPI (Invitrogen) in 1 PBS/1% BSA and incubated at room
temperature for 30min. Cells were then rinsed twice with 1 PBS
and mounted in VectaShield mounting media.
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Automated quantification of cellular morphology
Quantification of cellular morphology properties from low
magnification (10) fluorescent images was done using custom
software written in MatLab (Chen et al., 2013). Briefly, non-
uniformities in the intensity field of the fluorescent images were
corrected, and precise segmentation of cellular and nuclear
boundaries were conducted using the corresponding stains of actin
and DAPI channels. These segmented regions were then used for
quantification of cellular and nuclear parameters.
WST-1 assay
Premixed WST-1 cell proliferation assay kit (Clontech, Mountain
View, CA) was used to measure cell proliferation. 5 103 cells
were grown in 96-well plate (BD Falcon, San Jose, CA) on either
PHEMA-coated or uncoated conditions in quadruplicates. WST-1
reagent was added in a 1:10 dilution at 0, 8, 24, or 72 h and
incubated for 2 h before absorbance was measured using a
FLUOStar Omega microplate reader from BMG Labtech,
Germany. Absorbance was read at 440 nm, with wavelength
correction done against 650 nm. Background correction was also
performed for both wavelengths.
SDS–PAGE and immunoblot
Cell lysates were mixed with Laemmli buffer (BioRad) with b-
mercaptoethanol in a 1:1 volume ratio. Samples were then boiled
for 10min before cooling on ice. Samples were then transferred to
a 4–20%Mini PTOTEANTGX gradient gel (BioRad) and subjected
to electrophoresis. Semi-dry transfer of protein to nitrocellulose
membrane was done using the Trans-Blot Turbo system from
BioRad. After transfer, blots were stored in 1 PBS, 0.1% Tween-
20 wash buffer overnight at 4˚C. Blots were then blocked in 5%
milk dissolved in 1 PBS, 0.1% Tween-20, for 1 h at room
temperature. Rabbit polyclonal antibody to human GDF15 (Santa
Cruz Biotechnology, Inc., Dallas, Texas) was used at a 1:500
dilution and incubated for 1 h at room temperature. Lamin A/C
(Santa Cruz Biotechnology, Inc.) was used as loading control and
rabbit polyclonal antibody against lamin A/C was used at a 1:2,000
dilution. After primary antibody incubation, blots were washed for
5min using wash buffer five times with agitation. AHRP conjugated
goat anti-rabbit secondary antibody was applied to the membrane
in a 1:20,000 dilution and incubated for 1 h at room temperature
followed by 5min wash repeated five times. Membranes were
incubated with Supersignal West Dura extended duration
substrate (Thermo Scientific, Waltham, MA) and the blot was
exposed to Amersham Hyperfilm ECL chemiluminescence film
(GE, Pittsburgh, PA).
High throughput fluorescence microscopy
Fluorescent images of stained cells were acquired using a
Nikon TE300 epifluorescence microscope (Nikon, Melville, NY).
A 9-by-9 scanning grid comprising of 81 image fields (with a 10%
overlap with adjacent fields to reduce artificial fragmentation
of cell and nucleus) were generated using the NIS Elements
software. The size of each image field (based on the Nikon
QMiMc camera sensor) was 1280 1024 pixels, and the pixel size
using the 10 objective was 0.57mm, respectively. Two channels
(UV, RFP) were acquired for each image field, followed by a
calibration image of both channels respectively for use in
computationally reducing the non-uniformity of the illumination
field (Chen et al., 2013).
Enzyme linked immunosorbent assay (ELISA) for GDF15
A commercial sandwich ELISA kit (R&D Systems, Minneapolis,
MN) was used to detect human GDF15 in conditioned media and
serum and performed according to manufacturer’s protocol.
Absorbance was read using a FLUOStar Omega microplate reader
(BMG Labtech). Absorbance readings were taken at 450 nm and
wavelength correctionwas done against 540 nm. Blank corrections
were done for both wavelengths. A standard curve using
recombinant GDF15 was run concurrently in every plate using
dilution buffer provided by manufacturer and sample
concentration was calculated based on standard curve and dilution
factor.
Construction of PTFE chamber
Chambers were constructed from PTFE tubing (Zeus, Inc.,
Orangeburg, SC) by cutting into rings 5mm in length. One PTFE
membrane filter of 0.2mm pore size (Millipore, Billerica, MA) each
was used to cover the top and bottom of the chamber using
silicone adhesive (NuSil, Carpinteria, CA). A drop of silicone
adhesive was also applied to the side of the chamber wall to serve
as an injection plug septum. The silicone adhesive was allowed to
cure for 48 h followed by gamma irradiation sterilization.
Growing LNCaP or PC3 cells in PTFE chamber
Cells were introduced into PTFE chamber using a 26G needle
through the injection plug septum. Chambers were then
submerged in RPMI supplemented with 5% FBS and 1% penicillin/
streptomycin. To demonstrate that cells introduced into the
chamber could continuously secrete GDF15, 2 105 LNCaP or
PC3 were injected into these chambers and then submerged into
6ml of growth media. Media was changed weekly and 1ml aliquots
were harvested 24 h after addition of fresh media. Collected media
was centrifuged at 300g for 5min to separate any debris and
measured for GDF15 as picogramGDF15 secreted per onemillion
cells over 24 h. To measure cell count, chambers were
disassembled by removing PTFE filter membrane and cells were
harvested by gentle aliquoting without the use of trypsin.
Suspended cells could be harvested from the chambers by gentle
aspiration with no washing or addition of trypsin.
Subcutaneous implantation of PTFE chamber in athymic
nude mice
All animal treatment protocols were approved by the animal care
and use committee of The Johns Hopkins University. Chambers
containing LNCaP or PC3 were implanted subcutaneously into
athymic nude mice, FIVE per group, to see how the chambers will
affect serum GDF15. Athymic nude mice (Harlan Laboratories,
Indianapolis, IN) were first anesthesized using 100mg/kg of
ketamine and 10mg/kg of xylazine administered intraperitoneally
and the site of incision was sterilized with Wescodyne and 70%
ethanol. A 15mm incision was introduced near the right scapulae
and a space was formed underneath the subcutaneous layer using a
hemostat to dissociate connective tissue, forming a space
underneath the subcutaneous layer. The diffusion chamber
containing either 2 105 PC3 or LNCaP cells was inserted into the
space 5mm away from the incision site. The incision site was then
closed using sterile surgical clips. Mice were observed until they
regained consciousness and checked daily for discomfort or
inflammation at site of the implantation.
Measurement of subcutaneous tumor xenograft volume
in athymic nude mice
A separate group of athymic mice were used for this experiment.
For the PC3 subcutaneous xenograft, 2 105 PC3 cells were
injected into the dorsal flank of athymic nude mice. For LNCaP
subcutaneous xenograft, 2 105 LNCaP mixed with 200ml
Matrigel (BD Bioscience) were injected into the dorsal flank of
athymic nude mice. Fifteen mice were used per group. Each mouse
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was weighed and tumor volumewas measured weekly. Calculation
of tumor volume was achieved using the following equation: p/
6 lengthwidth height.
Immunohistochemistry in tumor xenografts
Animals were euthanized by CO2 asphyxiation and xenograft
tumors were excised from euthanized animals and placed in
formalin fixative followed by embedding in paraffin. Fixed tissues
were sent to Tissue Microarray Lab core facility at the Sidney
Kimmel Comprehensive Cancer Center at Johns Hopkins for
paraffin embedding, sectioning and H&E staining.
Immunohistochemistry was done using the EnVision G|2
Doublestain System from DAKO. Formalin fixed paraffin
embedded xenografts were first deparaffinized in xylene, two
times, 10min each, followed by rehydration in 100% ethanol, 95%
ethanol, and 70% ethanol, 5min each. Specimens were then further
rehydrated in deionized H2O twice for 5min each and heat-
mediated antigen unmasking was performed using 10mM sodium
citrate buffer pH 6.0 for 20min. After antigen unmasking,
endogenous enzyme activity was blocked using the dual
endogeneous enzyme block provided and a second blocking step
was done by incubating specimens using 5% milk, 0.05% Tween-20
in 1 TBS for 1 h at room temperature. After blocking, primary
antibody was added at the appropriate concentration (20mg/ml
mouse anti-human GDF15 monoclonal antibody (R&D Systems);
1mg/ml rabbit anti-human VEGF polyclonal antibody (Millipore)
for 1 h, followed by three washes with 0.05% Tween-20 in 1 TBS
wash solution. A mixture containing HRP-conjugated dextran
beads that contain antibodies to either mouse or rabbit
immunoglobulins was added to bind to the primary antibody.
Substrate solution was added and color was allowed to develop
for up to 15min. Specimens were counterstained with
hematoxylin and permanently mounted using Cytoseal from
Thermo Scientific.
Statistical analysis
Statistical analysis was performed with GraphPad PRISM
(GraphPad Software, Inc., La Jolla, CA). Two-tailed unpaired t-test
was used to analyze q-RT-PCR results of GDF15 expression as
well as morphological changes. Bonferroni’s multiple comparison
test was used to compare GDF15 expression between growth in
different collagen concentrations as well as secreted GDF15 from
different cell lines. P-values less than 0.05 are considered
statistically significant.
Results
Identification of growth differentiation factor 15 (GD15)
as target gene candidate following disruption of cell
morphology
To identify a target gene that changed in expression following
manipulation of cell morphology, LNCaP prostate carcinoma
cells were treated with 500 nM of latrunculin B (Lat B), a drug
that specifically disrupts the actin cytoskeleton (Morton et al.,
2000) for 8 h and gene expression compared between Lat B
or carrier treatments using an Agilent 4 44 k gene
expression microarray. Seven potentially up-regulated target
genes were first selected using the following criteria: a P-
value of less than 0.001, signal intensities above background
for both red and green channels, and using a cutoff of 1.5-fold
up-regulation. These seven target genes also demonstrated
either the highest fold up-regulation or had known
involvement with prostate cancer. These seven potential
target genes were then further verified using quantitative
reverse transcription PCR comparing between Lat B and
carrier treated LNCaP or PC3 cells. Growth differentiation
factor 15 (GDF15) was one of the target genes that was
consistently up-regulated in both Lat B treated LNCaP and
PC3 (Supplementary Fig. 1).
GDF15 does not affect cell attachment or proliferation
under non-attachment conditions
To clarify the causal relationship between morphology and
GDF15, cells were grown in different amounts of GDF15 to
determine the effects on cellular morphology. LNCaP, PC3,
and DU145 cells all produce different amounts of GDF15 while
grown on a tissue culture dish. LNCaP produces the most
GDF15, followed by PC3 and DU145 (Liu et al., 2003). Neither
PC3 nor DU145 cells grown in LNCaP conditioned media
exhibited any noticeable alterations to attachment or
morphology within 24 h (Supplementary Fig. 2). In addition,
neither transient nor long-term knockdown of GDF15 in PC3
or LNCaP altered morphology (Supplementary Fig. 2).
Rapid, reversible induction of GDF15 up-regulation
accompanied disruption of actin cytoskeleton
Jasplakinolide (Jpk) is another drug that disrupts cell shape by
targeting the actin cytoskeleton (Bubb et al., 2000). PC3
prostate carcinoma cells treated with either 500 nM Lat B or
100 nM Jpk displayed altered morphology as evidenced by the
rounding up of cell body within 8 h of drug exposure (Fig. 1i).
Increase in GDF15 mRNA and protein levels accompanied this
change in morphology (Fig. 1ii, iii), confirming microarray
results. Cells treated with Jpk or Lat B remained attached to
the tissue culture dish despite the morphological change. Cell
morphology recovered within 24 h following removal of drug
(Fig. 1i) and corresponded to significant decreases in GDF15
mRNA and protein levels (Fig. 1ii, iii). No significant toxicity
was associated with 8-h exposure to either drug (Fig. 1iv).
There is evidence that treating cells with actin perturbing
agents such as latrunculin or cytochalasins can activate PKC or
p38MAPK signal transduction (Lim et al., 2000, 2003). To
examine if these pathways were also responsible forGDF15 up-
regulation observed in Jpk treated PC3 cells, we first tested a
panel of inhibitors in an attempt to suppress GDF15 up-
regulation by Jpk. Of the inhibitors tested, those targeting
p38MAPK (SB203580) or PKC (H7) could partially suppress
GDF15 up-regulation by Jpk in a dose-dependent manner
(Supplementary Fig. 3), verifying previously reported findings of
the involvement of PKC or p38MAPK in regulating GDF15
expression. As a control, PMA was used to activate PKC
signaling transduction pathway. PMA was also known to be
capable of increasing GDF15 expression through the activation
of PKC in prostate cancer cells (Shim and Eling, 2005, 2008).
Treating PC3 cells with 300 nM PMA increased GDF15 protein
levels within 8 h (Fig. 1v). Adding 2mM p38MAPK (SB203580)
and 20mM PKC (H7) inhibitors in combination prevented
GDF15 up-regulation induced by PMA as well as Lat B and Jpk in
PC3 (Fig. 1v). Similar results were observed in two other
prostate carcinoma cell lines, LNCaP and DU145
(Supplementary Fig. 4), although there appear to be additional
pathways involved in regulation of GDF15 expression for
LNCaP as GDF15 up-regulation was not fully suppressed. This
indicates that disruption of cell morphology using Lat B or
Jpk activated signal transduction pathways such as the PKC/
p38MAPK resulting in GDF15 up-regulation. This up-regulation
can be reversed by inhibiting the PKC p38MAPK pathway or
allowing cells to recover cell morphology by removing the drug.
GDF15 expression accompanied changes in morphology
over time of attachment
To confirm GDF15 up-regulation was not due to Lat B or Jpk
directly activating PKC/p38MAPK pathway, we tested
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alternate approaches to alter cell morphology. The first
approach was to follow GDF15 expression and cell
morphology as cells were allowed to attach to a normal tissue
culture dish in a time dependent manner. Freshly trypsinized
PC3 cells were seeded onto a tissue culture dish and
harvested 8, 24, and 72 h post-seeding for analysis of GDF15
mRNA and protein levels. Cells harvested by scraping were
used as the 0-h time point control. At 8 h post-seeding, a
majority of PC3 cells were not fully attached to the tissue
culture dish and appeared more circular and smaller
morphologically (Fig. 2i). Correspondingly, GDF15 mRNA and
protein levels were elevated at 8 h (Fig. 2ii, iii). At 24 h of
attachment, PC3 cells had more time to attach and appeared
less circular and had a slightly larger cell size. This change in
morphology was accompanied by a decrease in both GDF15
mRNA and protein levels (Fig. 2ii, iii). To confirm these
qualitative morphological observations quantitatively, we
quantified three parameters of cell morphology: circularity,
size and perimeter and found that in concordance with
qualitative observations, a higher proportion of cells were
more circular and smaller at 8 h as compared to 24 h of
attachment (Fig. 2iv–vi).
Next, we examined whether maintaining a constant
rounded morphology could sustain GDF15 up-regulation.
Freshly trypsinized PC3were seeded on PHEMA-coated dishes
and harvested at 8, 24, and 72-h intervals to analyze for GDF15
expression. Cell harvested by scraping were used as the 0-h
time point control. Rounded morphology was maintained at all
time points of this experiment (Fig. 3i). Correspondingly,
GDF15 mRNA and protein levels remained elevated at all time
points as well (Fig. 3ii, iii). Cells grown on PHEMA-coated
dishes were still viable, although they proliferated slower
than cells grown on uncoated tissue culture dishes (Fig. 3vi).
Similar results were obtained with LNCaP and DU145 cells,
indicating that increasing GDF15 levels is a common response
prostate cancer cells exhibit when morphology was altered
(Supplementary Fig. 5).
To determine if PKC and p38MAPK were also activated
when cells lost attachment, we treated cells grown on PHEMA-
coated dishes with a combination of SB203580 and H7.
Interestingly, inhibiting the PKC p38MAPK signaling pathway
suppressed the up-regulation of GDF15 (Fig. 3iv, v). This
observation demonstrated that in PC3, the activation of PKC/
p38MAPK was induced by altered morphology and not a non-
Fig. 1. Disruption of cell morphology using drugs that target the actin cytoskeleton up-regulate GDF15 expression. (i) Images of PC3 cells
treated with carrier (ethanol), latrunculin B (Lat B) or jasplakinolide (Jpk) within 8 h of treatment (top row) and after 24-h recovery following
removal of drug by changing media (bottom row). White bar¼ 50mm. (ii) Quantitative real-time PCR (Q-PCR) showing elevated GDF15
mRNA transcript levels within 8 h of either Lat B or Jpk treatment relative to vehicle treated cells. Levels of GDF15 transcript decreased 24h
after removal of drug (P< 0.05). (iii) Immunoblot of PC3 cell lysate of different treatments probing for intracellular GDF15 protein levels and
lamin A/C as loading control. (iv) WST-1 assay of PC3 cells treated with carrier, Lat B or Jpk for 8 h. (v) Immunoblot for GDF15 in PC3 cells
following 8-h treatment using carrier, 300nM PMA, 500nM Lat B, or 100 nM Jpk with or without combination of 2mM SB203580 and 20mM
PKC inhibitors.
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specific effect of Lat B or Jpk. This inhibition was also seen in
DU145 but not LNCaP, indicating that other pathways exist
that could regulate GDF15 expression (Supplementary Fig. 5).
Another approach to alter cell morphology was to grow the
cells in a human collagen I matrix, a major component of the
bone matrix. When PC3 cells were grown in a collagen I
matrix, the cells again exhibited altered morphology such as
rounding of the cell body with increasing density of collagen
(Fig. 3vii), similar to that seen by drug treatment or growth on
PHEMA-coated plates and GDF15mRNA levels increased with
increasing collagen density (Fig. 3viii). This behavior was also
observed in LNCaP and DU145 cells (Supplementary Fig. 5).
Different types of cancer cell lines increase secretion of
GDF15 following altered cell morphology
To determine if secreted GDF15 was also increased when cell
morphology was altered, conditioned media from cells grown
on PHEMA-coated tissue culture dishes and uncoated tissue
culture dishes was measured for GDF15 using ELISA. Cells
were grown on either uncoated dishes or PHEMA-coated
dishes for 48 h. The media was then changed and the
conditioned media was harvested 24 h later and secreted
GDF15 was measured as picogram of GDF15 secreted per one
million cells over 24 h. As expected, PC3, LNCaP and DU145
grown on PHEMA-coated dishes demonstrated altered
morphology and secreted higher amounts of GDF15 (Fig. 4 i, ii).
When cells grown on PHEMA-coated dishes were cultured
back onto normal tissue culture dishes, cell morphology
returned and secretion of GDF15 decreased. This result
reinforced our findings that GDF15 up-regulation occurred
both at the mRNA and intracellular protein levels upon altered
morphology, and demonstrates a positive relationship between
intracellular protein levels and secreted protein. Similarly,
increased secretion of GDF15 was observed in HCT116 cells
grown on PHEMA-coated dishes (Fig. 4ii).
Fig. 2. Up-regulation of GDF15 following changes to cell morphology by attachment to a normal tissue culture dish. (i) PC3 cells were
seeded on a normal tissue culture dish and images taken at 8, 24, and 72 h after seeding. White bar¼ 50mm. (ii) Q-PCR of GDF15 mRNA
transcript levels from at 0, 8, 24, and 72h after seeding freshly trypsinized cells on tissue culture dish. Cells previously grown on a regular
tissue culture dish for 96h were harvested by scraping for 0-h time point. (iii) Immunoblot probing for GDF15 with lamin A/C as loading
control. Cell lysate was prepared from cells harvested at 0, 8, 24, or 72h after seeding on uncoated or PHEMA-coated dishes. (iv) Frequency
distribution curve of cell circularity comparing between cells at 8 and 24h of attachment (P< 0.05). (v) Frequency distribution curve of cell
area comparing between cells at 8 and 24h of attachment (P< 0.05). (vi) Frequency distribution curve of cell perimeter comparing between
cells at 8 and 24h of attachment (P< 0.05).
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Cells grown under conditions preventing attachment
in vivo can contribute to overall serum GDF15 levels
It is known that metastatic prostate cancer patients have higher
levels of serum GDF15 (Selander et al., 2007; Brown et al.,
2009). Our own analysis of GDF15 among 89 patients yielded
similar results (Supplementary Fig. 6, Supplementary Table 1).
It has also been documented that patients with metastatic
disease have higher numbers of CTCs (Allard et al., 2004; de
Bono et al., 2008), and these CTCs appear morphologically
different from the solid tumor counterparts (Marrinucci et al.,
2010). To examine if CTCs could affect serum GDF15 levels,
LNCaP or PC3 cells were introduced as a suspension into a
diffusion chamber made of polytetrafluoroethylene (PTFE).
PTFEwas chosen as thematerial of choice as cells attach poorly
to PTFE without prior chemical modifications (Chen et al.,
2003; Gabriel et al., 2011). 2 105 LNCaP or PC3 cells injected
into these chambers secreted GDF15 to a similar level attained
by growing on PHEMA-coated dishes (Fig. 5i). Cells harvested
from the chambers as a suspension retained ability to re-attach
to uncoated tissue culture dishes (Supplementary Fig. 7).
Chambers implanted in mice resulted in elevated serum
GDF15 (Fig. 5iv) within 10 days as compared to mice with
subcutaneously injected cells of similar numbers
(Supplementary Fig. 7).
To observe if a tumor xenograft would influence serum
GDF15 in a similar fashion, PC3 or LNCaP tumors were
incoculated subcutaneously into a separate group of mice.
Tumor volume and serum GDF15 were measured weekly. A
linear regression and correlation analysis yielded a positive
relationship between tumor volume and serum GDF15 levels
(Fig. 5ii, iii). For LNCaP xenograft tumors, linear regression
analysis yielded a slope of 28.8 1.1 (95% confidence interval,
P-value less than 0.001); the Pearson correlation coefficient
was 0.9087 while the r2 value was 0.8258 (P-value less than
0.001). For PC3 xenograft tumors, linear regression analysis
Fig. 3. Sustained up-regulation of GDF15 following prolonged changes to cell morphology by growing cells on PHEMA-coated dish. (i) PC3
cells were seeded on a PHEMA culture dish and images taken at 8, 24, and 72h after seeding. White bar¼ 50mm. (ii) Q-PCR of GDF15 mRNA
transcript levels from at 0, 8, 24, and 72h after seeding freshly trypsinized cells on PHEMA-coated dish. Cells previously grown on a regular
tissue culture dish for 96h were harvested by scraping for 0-h time point. (iii) Immunoblot probing for GDF15 with lamin A/C as loading
control. Cell lysate was prepared from cells harvested at 0, 8, 24, or 72 h after seeding on uncoated or PHEMA-coated dishes. (iv) Q-PCR of
GDF15 demonstrating effect of adding p38MAPK and PKC inhibitor combination to cells grown on PHEMA-coated dish (P< 0.05). (v) GDF15
immunoblot demonstrating that effect of p38MAPK and PKC inhibitor combination to GDF15 protein levels. (vi) WST-1 assay demonstrating
viability of cells grown on uncoated or PHEMA-coated dish. (vii) Images of PC3 cells grown in increasing collagen I concentration. (viii) Q-PCR
analysis of PC3 cells grown in different collagen I concentration matrix (P< 0.05).
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yielded a slope of 1.21 0.058 (95% confidence interval, P-
value less than 0.001); the Pearson correlation coefficient was
0.8145 while the r2 value was 0.6634 (P-value less than 0.001).
Using the linear regressionmodel analysis, it was estimated that
2 105 LNCaP cells grown in the chamber and implanted into
mice resulted in serumGDF15 levels corresponding to that of a
tumor mass of 19.9mm3. For PC3 cells, 2 105 cells in the
PTFE chamber implanted subcutaneously into mice resulted in
serum GDF15 levels corresponding to that of a tumor mass of
51.2mm3 (Fig. 5iv).
Heterogeneous expression of GDF15 in xenograft
tumors
To understand why xenograft tumors affected serum GDF15
levels to a lesser degree than cells grown in diffusion chambers,
immunohistochemical (IHC) staining for GDF15 was
performed on xenografts tumor sections. Visible staining was
only observed in LNCaP and none observed in PC3 xenografts
(Fig. 6). In LNCaP xenografts, little or no staining was observed
in the majority of the tumor with stronger staining for GDF15
observed in regions where cancer cells appear to be palisading
towards necrotic regions. This signal is specific to GDF15 as no
staining was observed using negative IgG controls. As a positive
control, xenografts were stained for VEGF, another cytokine
important for remodeling the extracellular environment that
is also controlled by environmental factors (Namiki et al.,
1995). VEGF staining within the xenograft was homogeneous
with slightly stronger staining noted near regions of necrosis
(Fig. 6).
Discussion
Our results demonstrate a new unique mechanism by which
the levels of GDF15 expression in cancer cells can be affected
through changes to cell morphology. There are multiple
mechanisms by which morphology can be altered and three
different strategies were employed in this study that altered
morphology while allowing cells to retain or lose cell adhesion.
Cell morphology was first affected by altering the actin
cytoskeleton through the use of drugs that target the actin
cytoskeleton, Lat B, and Jpk. This resulted in changes to
morphology with minimal impact on attachment. A second
method was to physically prevent attachment to a growth
substrate through the use of PHEMA. The third method was to
grow cells in a three-dimensional collagen I matrix gel. Cells
grown in this three-dimensional gel adopted a different
morphology but were still attached to the collagen I matrix.
Fig. 4. Different cell types increase GDF15 secretion following changes to morphology induced by preventing attachment. (i) Different types
of cancer cells demonstrate morphology changes when cells were grown on PHEMA-coated dishes as compared to growth on uncoated
normal dishes. This change in morphology is regained when cells on PHEMA-coated dishes were allowed to re-attach to uncoated normal
dishes. White bar¼ 50mm. (ii) Bar graphs depicting the amount of GDF15 secreted per cell type. Amount of GDF15 secreted increased when
cells were grown on PHEMA-coated dishes and decreased back to normal when cells were allowed to re-attach to normal dishes (P< 0.05).
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While these strategies are artificial and may not mimic in vivo
environment conditions, they are nevertheless effective
mechanisms of modulating cell morphology and allowed us to
study the consequences of altering cancer cell morphology.
We further demonstrated that such changes in morphology
most likely resulted in the activation of signal transduction
pathways such as PKC/p38MAPK and a resulting increase in
GDF15 production and secretion. GDF15 up-regulation in this
manner could be independent of p53, as observed in PC3 and
DU145, which have mutated p53 (Isaacs et al., 1991). This up-
regulation was sustained as long as cell morphology remained
altered, yet reversible when cell morphology was allowed to
return. This observation can also be extended to different
types of cancer cells and indicates GDF15 up-regulation is a
common response that cancer cells mount under conditions
that affect morphology. Little is known regarding the direct
relationship between changes in morphology and PKC/
p38MAPK activation, but there have been reports that the
disruption of the actin cytoskeleton or applying a mechanical
force can activate PKC/p38MAPK activity (Geng et al., 2001;
D’Addario et al., 2002; Wang et al., 2005). It is plausible a
change in morphology would equate to a change in mechanical
forces applied on a cell that remodels the actin cytoskseleton
and the activation of PKC or p38MAPK signaling. Mechanical
forces are also known to activate Rho signaling (McBeath et al.,
2004; Zare-Mehrjardi et al., 2011), raising the possibility that
PKC/p38MAPK and possibly other signal transduction
pathways responsive to changes in cell morphology may exist.
More work is needed to determine the exact nature of how
changes in morphology can activate signal transduction
pathways. It is also possible that changes in morphology can
induce a shift in integrin binding sites that may influence signal
transduction pathway activation.
Given that treating cells with PKC/p38MAPK inhibitors
reduced intracellular protein levels, and intracellular protein
levels are positively correlated with secreted GDF15, we
believe that p38MAPK inhibitors may be useful in reducing
serum GDF15 in patients. This is important because in recent
years, GDF15 has been increasingly associated as being a
potential marker for many metastatic cancers (Selander et al.,
2007; Brown et al., 2009; Kluger et al., 2011; Wallin et al.,
2011).
We also demonstrated that small number of cancer cells
maintained in vivo in an unattached condition could contribute
Fig. 5. Small number of cells grown under conditions preventing attachment in vivo can result in an increase in serum GDF15. (i) Amount of
GDF15 secreted into conditioned media when 2 105 PC3 or LNCaP cells introduced into PTFE diffusion chambers were grown in vitro for
3 weeks. (ii) Scatter plot of tumor volume against serum GDF15 concentration in PC3 xenografts (n¼ 11). Linear regression analysis was
performed and a best-fit line drawn as a solid line. Dashed line indicates 95% confidence interval of best-fit line. (iii) Scatter plot of tumor
volume against serum GDF15 concentration in LNCaP xenografts (n¼ 12). Linear regression analysis was performed and best-fit line drawn as
solid line. Dashed line indicates 95% confidence interval. (iv) Bar graph of GDF15 in pooled serum of mice implanted with chambers containing
2 105 PC3 or LNCaP, n¼ 5 for each group.
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to overall serum GDF15 levels comparable to that of a tumor
mass. While the conditions in our experiment may not truly
mimic the physiological conditions CTCs experience in vivo,
we believe these results still support the possibility that CTCs
could contribute to overall serum GDF15 concentration. We
believe that this would justify future work proposing to study
the relationship between serum GDF15 and CTCs in cancer
patients.
Strong GDF15 staining within xenograft tumors was
observed in regions where cells were palisading, which
indicates the possibility that cells could be in the process of
migration or invasion.We cannot conclude definitively that the
cells are actively invading as IHC only allows us to study cells in
a static state but the appearance of the cells do indicate the
possibility of some cellular movement. Interestingly, cells in
GDF15 positive regions also appear morphologically different
from the GDF15 negative cells from visual examination. This
staining was observed specifically in these regions and a vast
majority of the tumor was negative for GDF15 staining. There
is a significant portion of the tumor that is negative for GDF15
staining. While this did not demonstrate changes in cell
morphology driving GDF15 expression in vivo, it reinforces the
dynamic nature of GDF15 expression when compared to
VEGF, another growth factor that can be influenced by the
environment. Importantly, in vitro, VEGF up-regulation was
not induced by changes to morphology brought about by loss
of attachment (Supplementary Fig. 8). This difference further
highlights the uniquemechanism bywhich GDF15 expression is
regulated through cell morphology, and is evidence that cells
display different phenotypes in response to different changes to
the external environment.
GDF15, also known as macrophage inhibitory cytokine-1
(MIC-1), is a member of the tumor growth factor beta (TGF-
b) super-family and is expressed at low levels in normal tissue
except placenta and seminal fluids (Hromas et al., 1997;
Soucek et al., 2010). Early reports suggest that GDF15 plays a
role in regulating immune response by inhibiting macrophage
activation by TNF-a (Bootcov et al., 1997). In animal models
of heart ischemia, GDF15 demonstrated a cardio-protective
role after ischemia induction by regulating the recruitment
and response of neutrophils to the site of injury (Khan et al.,
2009; Kempf et al., 2011). This finding was extended to cancer
as GDF15 could also contribute to the evasion of glioma cells
from the immune system (Roth et al., 2010). It was also
Fig. 6. Histological staining of LNCaP and PC3 xenografts. H&E and Immunohistochemistry staining for GDF15, VEGF, and IgG negative
control, respectively. Large regions of tumor do not stain for GDF15. Strong staining for GDF15 was observed near regions where cells were
palisading towards necrotic regions. Little staining for GDF15 was observed anywhere else in the xenograft. Strong VEGF staining was
observed throughout the xenograft, but was stronger near regions that corresponded to strong GDF15 staining. Scale bar¼ 1,000mm (low
magnification), 100mm.
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demonstrated that GDF15 has a role in inducing cachexia,
another common symptom seen in late stage cancer patients
(Johnen et al., 2007; Wakchoure et al., 2009). GDF15 could
also regulate osteoclast formation demonstrating its
importance in bone metastases, a common site of cancer
metastatic lesions (Coleman, 2001; Mundy, 2002; Wakchoure
et al., 2009). Recently, elevated serum GDF15 has been
increasingly associated as a potential marker for many
metastatic cancers, including but not limited to colon,
melanoma and prostate cancer (Selander et al., 2007; Brown
et al., 2009; Kluger et al., 2011; Wallin et al., 2011). This
commonality among different cancer types highlights the
importance of GDF15 in the field of cancer. In addition, a
common complication cancer patients encounter when
undergoing chemotherapy is the emergence of
chemoresistant cancer cells. Interestingly, GDF15 has also
been suggested to be responsible for conferring drug
resistance to cancer cells (Proutski et al., 2009; Zhao et al.,
2009). Not surprisingly then, elevated serum GDF15 has also
been associated with a higher overall mortality risk which is
indicative of the growing importance of GDF15 (Wiklund
et al., 2010).
Given the potential roles of GDF15 in cancer and the ability
to cancer cells to up-regulate expression of this gene upon
encountering changes to morphology may explain how tumor
cells escape the host immune response until successful
colonization of a secondary site. Once metastases occur,
cancer cells may continue to secrete GDF15 depending on the
physical microenvironment, such as bone, which comprises of
collagen I (Viguet-Carrin et al., 2006). Since GDF15 has also
been reported to be involved in bone remodeling and
cachexia, it may explain why metastatic prostate cancer
patients experience loss of bone density and body weight
(Wakchoure et al., 2009). Finally, the role of GDF15 in
chemoresistance (Proutski et al., 2009; Zhao et al., 2009)
could mean that chemoresistance is an inevitable outcome of
any chemotherapy regimen that induces altered cell
morphology. It may also mean that CTCs could be intrinsically
chemoresistant. More work is needed to examine this
relationship in detail.
We would like to propose the following model based on
three observations: (1) CTCs exist within the circulatory
system of cancer patient and there appears to be a positive
relationship between the number of CTCs observed and the
presence of metastatic disease (Allard et al., 2004; de Bono
et al., 2008). (2) Patients with metastatic cancers have higher
serum GDF15 levels. (3) As we observed in our work,
cancer cells that experience a change in morphology up-
regulate GDF15 expression as a consequence. Therefore, we
propose that increased serum GDF15 in cancer patients is
possibly a consequence of ongoing metastasis. As cancer
cells start to intravasate into the circulatory system, they
inevitably experience changes to cell morphology. This
change in morphology activates signal transduction pathways
that may result in GDF15 up-regulation. Furthermore,
morphologically different circulatory tumor cells may also
secrete GDF15 directly into the circulation that may possibly
influence serum GDF15 levels directly, indicating that GDF15
could be used as a signature of invasive cells during
metastasis or CTCs. Therefore, serum GDF15 could be used
to identify cancer patients who require more aggressive
treatment from those that do not. More work is needed to
elucidate the exact nature of the relationship between serum
GDF15 and CTCs.
We believe that GDF15 is but one of the many genes that
exhibit altered expression in the face of changes in cell
morphology. Identifying which other genes respond in the
same way is important and will help us better understand
cancer biology, particularly the onset of metastasis.
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